28 January 2022
Synairgen plc
("Synairgen" or the "Company")
Director/PDMR Dealing
Southampton, UK - 28 January 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001 (inhaled interferon-beta or IFN-beta) for the treatment of COVID-19 as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs, announces that it was notified on 27 January 2022 that the spouse of Brooke Clarke, Senior Vice President, Head of Communications and PDMR, had purchased 8,520 ordinary shares of 1 pence each in the Company ("Ordinary Shares") at an average price of 189.717p.
Following the purchase, the spouse of Brooke Clarke has a total interest over 8,520 Ordinary Shares, representing 0.004 per cent. of the Company's issued share capital.
For further information, please contact:
Synairgen plc
Richard Marsden, Chief Executive Officer
John Ward, Chief Financial Officer
Brooke Clarke, Head of Communications
Tel: +44 (0) 23 8051 2800
finnCap (NOMAD and Joint Broker)
Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance)
Alice Lane, Sunil de Silva (ECM)
Tel: +44 (0) 20 7220 0500
Numis Securities Limited (Joint Broker)
James Black, Freddie Barnfield, Duncan Monteith
Tel: +44 (0) 20 7260 1000
Consilium Strategic Communications (Financial Media and Investor
Relations)
Mary-Jane Elliott, Jessica Hodgson, Lucy Featherstone
synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5700
MK Strategies, LLC (US Media Relations)
Mary Conway
MConway@MKCStrategies.com
Tel: +1 516 606 6545
The notification set out below is provided in accordance with the requirements of the UK Market Abuse Regulation.
|
1 |
Details of the person discharging managerial responsibilities/person closely associated | ||
|
(a) |
Name |
Thomas Clarke | |
|
2 |
Reason for the notification | ||
|
a) |
Position/status |
Person closely associated with Brooke Clarke, a PDMR | |
|
b) |
Initial notification/Amendment |
Initial notification | |
|
3 |
Details of issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
|
a) |
Name |
Synairgen plc | |
|
b) |
LEI |
213800IMMTOPPDF8HD24 | |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted. | ||
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary shares of 1p
ISIN: GB00B0381Z20 | |
|
b) |
Nature of the transaction |
Purchase of shares by spouse | |
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
|
|
£1.8974 £1.8942 |
7,899 621 |
|
|
|
|
|
|
d) |
Aggregated information - Aggregated volume - Price |
8,520 Ordinary Shares £16,163.86p | |
|
e) |
Date of the transaction |
27 January 2022 | |
|
f) |
Place of the transaction |
XLON | |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.